SecuritySYBX / Synlogic, Inc. (60470J103)
IndustryPharmaceutical Preparations
Common Stock Shares Outstanding25,432,849 shares (as of 2018-06-30)
Total Insiders48
Total Directors16
Total Officers12

Stock Insider Trading (from SEC Form 4)

SYBX / Synlogic, Inc. Insider Trades

Synlogic, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SYBX / Synlogic, Inc. insiders include Atlas Venture Fund IX, L.P., O'Neill Vincent, ORBIMED ADVISORS LLC, Brennan Aoife, Shegog Todd, SANDELL SCOTT D, POWELL MICHAEL, Fuhrman Alan, NEA 14 GP, LTD, Lammers Paul, Winkler Matthew, NEA Partners 14, L.P., and KERINS PATRICK J, DeYoung Casi, HEALY JAMES, Gengos Andrew, BARRETT M JAMES, KOLLURI KRISHNA KITTU, Leschly Nick, Shea Richard P, ISALY SAMUEL D, PFIZER INC, Mathers Edward T, Weller Harry R, Gutierrez-Ramos Jose-Carlos MOTT DAVID M, Sofinnova Venture Partners VIII, L.P., Viswanathan Ravi, Kim Sinil, Florence Anthony A. Jr., Barrett Peter, Sonsini Peter W., OrbiMed Capital GP VI LLC, Greenleaf Peter, BARRIS PETER J, AKKARAJU SRINIVAS, Miller Paul Francis, Barbosa Miguel, Nisen Perry, Jones Elaine V, BASKETT FOREST, Mehra Anand, New Enterprise Associates 14, L.P., Irvin Jon, Sofinnova Management VIII, L.L.C., SIEGALL CLAY B, Khuong Chau Quang, Alleva Lawrence M, .

Insider Roster

Insider Dir Off 10% Shares Owned
Miller Paul Francis Chief Scientific Officer
X 60,135
Leschly Nick Director
X
Barrett Peter Director
X
POWELL MICHAEL Director
X
Khuong Chau Quang Director
X
Shea Richard P Director
X
Mathers Edward T Director
X
Brennan Aoife Interim President and CEO
X
Gutierrez-Ramos Jose-Carlos See Remarks, Director
X X
Shegog Todd See Remarks
X
Gengos Andrew Chief Operating Officer
X
ORBIMED ADVISORS LLC Director
OrbiMed Capital GP VI LLC Director
X 2,029,996
Viswanathan Ravi 10% Owner
X 4,228,940
Sonsini Peter W. 10% Owner
X 4,228,940
SANDELL SCOTT D 10% Owner
X 4,228,940
MOTT DAVID M 10% Owner
X 4,228,940
KERINS PATRICK J 10% Owner
X 4,228,940
Florence Anthony A. Jr. 10% Owner
X 4,228,940
BASKETT FOREST 10% Owner
X 4,228,940
BARRIS PETER J 10% Owner
X 4,228,940
BARRETT M JAMES 10% Owner
X 4,228,940
NEA Partners 14, L.P. 10% Owner
New Enterprise Associates 14, L.P. 10% Owner
NEA 14 GP, LTD 10% Owner
X 4,228,940
Atlas Venture Fund IX, L.P. 10% Owner
X 5,303,926
ISALY SAMUEL D Director
ORBIMED ADVISORS LLC Director
OrbiMed Capital GP VI LLC Director
X 2,629,992
Irvin Jon Vice President, Finance
X
Nisen Perry Director
X
Winkler Matthew Director
X
Alleva Lawrence M Director
X
SIEGALL CLAY B Director
X
Greenleaf Peter Director
X
O'Neill Vincent Chief Medical Officer
X
DeYoung Casi Chief Business Officer
X
Fuhrman Alan Chief Financial Officer
X
Lammers Paul President & CEO, Director
X X
PFIZER INC 10% Owner
X
Sofinnova Venture Partners VIII, L.P. 10% Owner
Mehra Anand 10% Owner
AKKARAJU SRINIVAS 10% Owner
HEALY JAMES 10% Owner
Sofinnova Management VIII, L.L.C. 10% Owner
X
New Enterprise Associates 14, L.P. 10% Owner
X
KOLLURI KRISHNA KITTU 10% Owner
X
Weller Harry R 10% Owner
X
Jones Elaine V Director
X
Barbosa Miguel Chief Scientific Officer
X
Kim Sinil Chief Medical Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-09-18 4 Miller Paul Francis S X D 13.0543 -3,000 60,135 785,020
2018-09-05 4 Miller Paul Francis S X D 12.5451 -3,000 63,135 792,035
2018-08-30 4 Miller Paul Francis S X D 9.7555 -1,342 66,135 645,180
2018-08-29 4 Miller Paul Francis S X D 9.7698 -1,658 67,477 659,237
2018-07-18 4 Miller Paul Francis S X D 11.0073 -3,000 69,135 760,990
2018-06-20 4 Miller Paul Francis S X D 9.75 -1,000 72,135 703,316
2018-06-20 4 Miller Paul Francis S X D 9.80 -1,054 72,135 706,923
2018-06-19 4 Miller Paul Francis S X D 9.75 -946 74,189 723,343
2018-01-26 4 ORBIMED ADVISORS LLC See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 Khuong Chau Quang See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 POWELL MICHAEL A I 9.75 150,000 574,972
2018-01-26 4 New Enterprise Associates 14, L.P. A D 9.75 410,000 4,228,940
2018-01-26 4 BARRETT M JAMES See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BARRIS PETER J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BASKETT FOREST See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Florence Anthony A. Jr. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 KERINS PATRICK J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 MOTT DAVID M See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 SANDELL SCOTT D See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Sonsini Peter W. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Viswanathan Ravi See Note 1 A I 9.75 410,000 4,228,940
2017-08-28 4 Sonsini Peter W. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Viswanathan Ravi See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRETT M JAMES See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRIS PETER J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BASKETT FOREST See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Florence Anthony A. Jr. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 KERINS PATRICK J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 MOTT DAVID M See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 SANDELL SCOTT D See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 New Enterprise Associates 14, L.P. A D 3,394,439 3,818,940
2016-12-01 4 Irvin Jon S D 1.4343 280 7,625 10,937
2016-11-11 4 Irvin Jon S D 1.45 -150 7,905 11,462
2016-11-01 4 Irvin Jon S D 1.2839 -280 8,055 10,342
2016-10-11 4 Irvin Jon S D 1.825 -150 8,335 15,211
2016-10-03 4 Irvin Jon S D 1.9254 -250 8,485 16,337
2015-10-06 4 PFIZER INC J D 7.0000 235,855 2,489,364
2015-10-06 4 PFIZER INC P D 7.0000 714,285 2,253,509 15,774,563
2015-10-05 4 PFIZER INC C D 1,539,224 1,539,224
2015-10-06 4 Weller Harry R See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Weller Harry R See Note 2 J I 31,650 2,114,375
2015-10-06 4 Weller Harry R See Note 2 J I 257,516 1,499,166
2015-10-05 4 Weller Harry R See Note 2 C I 583,559 2,082,725
2015-10-05 4 Weller Harry R See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 Viswanathan Ravi See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Viswanathan Ravi See Note 2 J I 31,650 2,114,375
2015-10-06 4 Viswanathan Ravi See Note 2 J I 257,516 1,499,166
2015-10-05 4 Viswanathan Ravi See Note 2 C I 583,559 2,082,725
2015-10-05 4 Viswanathan Ravi See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 P I 7.00 857,142 2,971,517 20,800,619
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

2018-09-07 seekingalpha
Discussion: On September 4, Recro Pharma (REPH) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the company now plans to submit a revised NDA by the end of this month. Suggestions offered by the FDA now guides the company to include revised labelling language and further information on extractable and leachable items. (123-10)

Your Daily Pharma Scoop: Motif Bio NDA Under Review, MiMedx Nixed, Biogen Halts

2018-08-16 seekingalpha
Discussion: FDA accepted for filing the NDA of Motif Bio’s (MTFB) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and skin structure infections (‘ABSSSIs). The application will be treated under priority review and now has a target PDUFA on February 19, 2019. Earlier, FDA granted Qualified Infectious Disease Product designation and fast track status to the drug. (24-4)

Rubius IPO: A Bit Expensive And At An Early Stage

2018-07-11 seekingalpha
Rubius is still at an early stage. A new investigational drug application will be filed in the first quarter of 2019 and INDs for additional product candidates will be filed. (2-0)

Why Synlogic (SYBX) Could Be a Potential Winner

2018-06-05 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. (13-3)

The Eleven: Viking Skyrockets, Global Blood Is Fueling

2018-06-04 seekingalpha
The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk tolerance. The first five picks are the top picks (in no particular order). Risks are increased the further away a stock sits from the middle (Picks #6, in the middle of the list, is the least risky). (96-9)